https://pubmed.ncbi.nlm.nih.gov/37853676/
These data demonstrate OMDI efficacy and safety in latanoprost low/nonresponders with POAG or OHT, suggesting OMDI is a treatment option in the patient...
omidenepag isopropyllatanoprostlowprimaryopen
https://www.gov.uk/drug-safety-update/latanoprost-xalatan-increased-reporting-of-eye-irritation-since-reformulation
Advise patients to tell their health professional if they experience severe eye irritation.
eye irritationlatanoprostxalatanincreasedreporting